報價延遲最少15分鐘:2026/04/21 19:26 EDT
盤後時段
|
||||
|
5.13 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.13
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.20/-1.20
|
|
企業價值
128.96M
|
| 資產負債 |
|
每股賬面淨值
-0.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
39.99K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developingdrug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma. |
